ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02163694
Previous Study | Return to List | Next Study

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02163694
Recruitment Status : Active, not recruiting
First Posted : June 16, 2014
Last Update Posted : May 16, 2018
Sponsor:
Information provided by (Responsible Party):
AbbVie

Brief Summary:
The study seeks to evaluate the efficacy and tolerability of veliparib/placebo in combination with carboplatin and paclitaxel in HER2-negative metastatic or locally advanced, unresectable, BRCA-associated breast cancer.

Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Drug: Paclitaxel Drug: Veliparib Drug: Carboplatin Other: Placebo Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 513 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Actual Study Start Date : August 5, 2014
Estimated Primary Completion Date : May 30, 2019
Estimated Study Completion Date : May 30, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Placebo Comparator: Placebo with Carboplatin and Paclitaxel
Placebo on Day -2 through 5 of a 21-day cycle. In addition, carboplatin and paclitaxel will be administered on Day 1 of a 21-day cycle.
Drug: Paclitaxel
Day 1 of 21-day cycle
Other Name: Taxol

Drug: Carboplatin
Day 1 of 21-day cycle

Other: Placebo
Placebo on Day -2 through 5 of a 21-day cycle. In addition, carboplatin and paclitaxel will be administered on Day 1 of a 21-day cycle.

Experimental: Veliparib with Carboplatin and Paclitaxel
Veliparib on Day -2 through 5 of a 21-day cycle. In addition, carboplatin and paclitaxel will be administered on Day 1 of a 21-day cycle.
Drug: Paclitaxel
Day 1 of 21-day cycle
Other Name: Taxol

Drug: Veliparib
Veliparib on Day -2 through 5 of a 21-day cycle. In addition, carboplatin and paclitaxel will be administered on Day 1 of a 21-day cycle.
Other Name: ABT-888

Drug: Carboplatin
Day 1 of 21-day cycle




Primary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: Measured up to 5 years after the last subject has enrolled in the study. ]
    Number of days from the date the subject is randomized to the date the subject experiences a confirmed event of disease progression or to the date of death if disease progression is not reached


Secondary Outcome Measures :
  1. Duration of overall response (DOR) [ Time Frame: Measured up to 2 years after the last subject has enrolled in the study. ]
    Number of days from the day the criteria are met for complete response or partial response (whichever is recorded first) to the date of progressive disease

  2. Progression-free survival 2 (PFS2) [ Time Frame: Measured up to 5 years after the last subject has enrolled in the study. ]
    Days from randomization to the second objective radiographic progression or death of any cause after the first objective radiographic progression, whichever occurs first

  3. Objective response rate (ORR) [ Time Frame: Measured up to 2 years after the last subject has enrolled in the study. ]
    Proportion of subjects with a complete or partial objective response

  4. Overall survival (OS) [ Time Frame: Measured up to 5 years after the last subject has enrolled in the study. ]
    Number of days from the day the subject is randomized to the date of the subject's death

  5. Clinical benefit rate (CBR) [ Time Frame: Measured up to 5 years after the last subject has enrolled in the study. ]
    Progression-free rate at 24 weeks from the Kaplan-Meier curve for time to progression


Other Outcome Measures:
  1. Change in quality of life (QOL) [ Time Frame: Measured up to 5 years after the last subject has enrolled in the study. ]
    Assessed via survey

  2. Change in Eastern Cooperative Oncology Group (ECOG) Performance Status [ Time Frame: Measured up to 2 years after the last subject has enrolled in the study. ]
    Change in ECOG performance status



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or cytologically confirmed breast cancer that is either locally advanced or metastatic. Locally advanced breast cancer must not be amenable to surgical resection or radiation with curative intent.
  2. Suspected deleterious or deleterious BRCA1 and/or BRCA2 germline mutation.
  3. Breast cancer must be HER2-negative.
  4. Measurable or non-measurable (but radiologically evaluable) disease per Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1 on computed tomography (CT) scan (within 28 days of randomization) with at least one lesion outside previously irradiated areas.
  5. ECOG Performance status of 0 to 2.
  6. Adequate hematologic, renal, and hepatic function (within 28 days of randomization).

Exclusion Criteria:

  1. More than two prior lines of cytotoxic chemotherapy (e.g., gemcitabine, doxorubicin, capecitabine) for metastatic disease.

    • Regimens received in the adjuvant/neoadjuvant setting or for locally advanced breast cancer within the past 6 months will also be considered toward the maximum of 2 prior lines of therapy. Adjuvant/neoadjuvant chemotherapy for one cancer event will count as one prior line of therapy, if received within the past 6 months.
    • Previous treatments with hormonal therapy (tamoxifen, aromatase inhibitors) and signal transduction agents (e.g., erlotinib, gefitinib, everolimus, bevacizumab) are allowed and are not counted towards the prior line of therapy.
  2. Progressed or recurred within 12 months of completing platinum therapy or received > 1 prior line of platinum therapy for breast cancer in any setting (adjuvant or neoadjuvant).
  3. Prior therapy with PARP inhibitors.
  4. Prior taxane therapy administered for the treatment of metastatic breast cancer with the below exceptions.

    • Prior taxane therapy for metastatic breast cancer is allowed if the patient received ≤ 1 full cycle (i.e., therapy discontinued within 4 weeks for subjects receiving weekly paclitaxel or Abraxane; therapy discontinued within 3 weeks for subjects receiving paclitaxel or docetaxel every 3 weeks) in the absence of progression or if taxane therapy for metastatic disease was > 12 months prior to C1D-2.
    • Use of taxanes as adjuvant therapy or to treat locally advanced disease is permitted, if given more than 6 months prior to C1D-2
  5. Known history of allergic reaction to cremophor-paclitaxel, carboplatin, Azo-Colourant Tartrazine (also known as FD&C Yellow 5 or E102), Azo-Colourant Orange Yellow-S (also known as FD&C Yellow 6 or E110) or known contraindications to any study supplied drug.
  6. Active CNS metastases or leptomeningeal disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02163694


  Hide Study Locations
Locations
United States, California
City of Hope
Duarte, California, United States, 91010
UCSD
La Jolla, California, United States, 92037
Hematology and Oncology Assoc
Newport Beach, California, United States, 92663
Cancer Research Collaboration,
Santa Ana, California, United States, 92705
ICRI
Whittier, California, United States, 90603
United States, Colorado
Univ of Colorado Cancer Center
Aurora, Colorado, United States, 80045
Saint Joseph Hospital
Denver, Colorado, United States, 80218
United States, Connecticut
Norwalk Hospital
Norwalk, Connecticut, United States, 06856
United States, Florida
Lynn Cancer Institute, Boca
Boca Raton, Florida, United States, 33486
Moffitt Cancer Center
Tampa, Florida, United States, 33612
Florida Cancer Specialists - East
West Palm Beach, Florida, United States, 33401
United States, Georgia
Emory University Hospital
Atlanta, Georgia, United States, 30322
The Cancer Ctr at DeKalb Med C
Decatur, Georgia, United States, 30033
United States, Illinois
University of Illinois
Chicago, Illinois, United States, 60607
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Baystate Medical Center
Springfield, Massachusetts, United States, 01199
UMass Memorial Medical Center
Worcester, Massachusetts, United States, 01655
United States, Michigan
Henry Ford Health System
Detroit, Michigan, United States, 48202
Spectrum Health Medical Group
Grand Rapids, Michigan, United States, 49503
William Beaumont Hospital
Royal Oak, Michigan, United States, 48073-6710
United States, Missouri
St. Lukes Cancer Institute
Kansas City, Missouri, United States, 64111-5905
Washington University-School of Medicine
Saint Louis, Missouri, United States, 63110
United States, Nebraska
Nebraska Hematology Oncology
Lincoln, Nebraska, United States, 68506
United States, New Mexico
University of New Mexico
Albuquerque, New Mexico, United States, 87102
United States, New York
Beth Israel Medical Center
New York, New York, United States, 10003
Mount Sinai St. Luke's
New York, New York, United States, 10025
United States, North Carolina
Cancer Care of WNC, PA
Asheville, North Carolina, United States, 28801
Duke Univ Med Ctr
Durham, North Carolina, United States, 27710
United States, Ohio
University of Toledo
Toledo, Ohio, United States, 43614
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239-3098
United States, Pennsylvania
Penn State University and Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
University of Pittsburgh MC
Pittsburgh, Pennsylvania, United States, 15260
United States, Texas
Texas Health Physicians Group
Arlington, Texas, United States, 76012
UT Southwestern Medical Center
Dallas, Texas, United States, 75390-7208
Univ TX, MD Anderson
Houston, Texas, United States, 77030
United States, Vermont
University of Vermont Medical Center
Burlington, Vermont, United States, 05401-1473
United States, Washington
Swedish Medical Center
Seattle, Washington, United States, 98104
Northwest Medical Specialties
Tacoma, Washington, United States, 98405
Argentina
COIBA
Berazategui, Buenos Aires, Argentina, 1884
Centro Oncologico Riojano
La Rioja, Argentina, 5300
Centro Investigacion Pergamino
Pergamino, Argentina, 2700
Instituto de Oncologia de Rosa
Rosario, Santa FE, Argentina, 2000
Australia, New South Wales
St George Hospital
Kogarah, New South Wales, Australia, 2217
The Prince of Wales Hospital
Randwick, New South Wales, Australia, 2031
Southern Medical Day Care Ctr
Wollongong, New South Wales, Australia, 2500
Australia, Queensland
The Townsville Hospital
Douglas, Queensland, Australia, 4814
Australia, South Australia
Flinders Centre for Innovation
Adelaide, South Australia, Australia, 5042
Australia, Tasmania
Royal Hobart Hospital
Hobart, Tasmania, Australia, 7000
Australia, Victoria
Royal Melbourne Hospital
Parkville, Victoria, Australia, 3050
Australia, Western Australia
Hollywood Private Hospital
Nedlands, Western Australia, Australia, 6009
Austria
AKH Wien
Vienna, Wein, Austria, 1090
LKH-Univ. Klinikum Graz
Graz, Austria, 8036
KH der Elisabethinen Linz GmbH
Linz, Austria, 4020
LKH Salzburg and Paracelsus
Salzburg, Austria, 5020
Belarus
Bobruysk Interdistrict Onco.
Bobruisk, Belarus, 213825
Belarus Cancer Center N.N. Alexandrov
Lesnoy, Belarus, 223040
Mogilev Reg Clin Oncology Dis
Mogilev, Belarus, 212018
Vitebsk Reg Clin Onc Disp
Vitebsk, Belarus, 210603
Belgium
Cliniques Universitaires Saint Luc
Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium, 1200
Grand Hôpital de Charleroi
Charleroi, Hainaut, Belgium, 6000
ZNA Middelheim
Antwerp, Belgium, 2020
UZ Antwerp
Edegem, Belgium, 2650
UZ Leuven
Leuven, Belgium, 3000
CHU UCL Namur
Namur, Belgium, 5000
Canada, Ontario
Sunnybrook Health Sciences Ctr
Toronto, Ontario, Canada, M4N 3M5
Canada, Quebec
Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
CHUM - Notre-Dame Hospital
Montréal, Quebec, Canada, H2X 0A9
CHUQ-Hospital St. Sacrement
Quebec City, Quebec, Canada, G1S 4L8
Chile
Instituto Nacional del Cancer
Santiago, Chile, 1010
ICOS - Inst Clinic Oncology
Temuco, Chile, 4810469
Hospital Clinico Vina del Mar
Vina Del Mar, Chile, 2520612
Colombia
Administradora del Country_S.A-Clinica Del Country
Bogota, Cundinamarca, Colombia, 110221
Hospital Univ San Ignacio
Bogota, Colombia, 110231
Centro Medico Imbanaco de Cali
Cali, Colombia
Hospital Pablo Tobon Uribe
Medellín, Colombia
Inst Med Alta Tec Onc (IMAT)
Monteria, Colombia
Czechia
Fakultni Nemocnice Olomouc
Olomouc, Olomoucky Kraj, Czechia, 779 00
Fakultni Nemocnice Brno
Brno, Czechia, 625 00
Masarykuv onkologikcy ustav
Brno, Czechia, 656 53
Vseobecna Fakultni Nemocnice
Prague, Czechia, 128 08
Denmark
Vejle Sygehus
Vejle, Syddanmark, Denmark, 7100
Rigshospitalet, Finsen Centre
Copenhagen, Denmark, 2100
Estonia
East Tallinn Central Hospital
Tallinn, Estonia, 10138
Finland
Docrates Cancer Center
Helsinki, Finland, 00180
Helsinki Univ Central Hospital
Helsinki, Finland, 00290
Tampere University Hospital
Tampere, Finland, 33521
Vaasa Central Hospital
Vaasa, Finland, 65130
France
Institut de Cancer de l'Ouest
St Herblain CEDEX, Loire-Atlantique, France, 44805
Institut Paoli-Calmettes
Marseille, France, 13273
Institut Curie
Paris, France, 75248
Hopital Rene Huguenin
Saint-cloud, France, 92210
Germany
Universitaetsklinik Heidelberg
Heidelberg, Baden-Wurttemberg, Germany, 69120
Uniklinik Koln
Köln, Nordrhein-Westfalen, Germany, 50937
Universitaetsklinikum Ulm
Ulm, Thuringen, Germany, 89081
Universitaetklinikum Dresden
Dresden, Germany, 01307
Klinikum recht der Isar der TU
Munich, Germany, 80802
Sana Klinikum Offenbach
Offenbach, Germany, 63069
Universitatsklinikum Tubingen
Tuebingen, Germany, 72076
Hungary
Pecsi Tudomanyegyetem
Pécs, Pecs, Hungary, 7624
Semmelweis Egyetem
Budapest, Hungary, 1085
Jasz-Nagykun-Szolnok Megyei
Szolnok, Hungary, 5004
Zala Megyei Korhaz
Zalaegerszeg, Hungary, 8900
Israel
Tel Aviv Sourasky Medical Ctr
Tel Aviv-Yafo, Tel-Aviv, Israel, 6423906
Soroka Medical Ctr
Be'er Sheva, Israel, 84101
Assaf Harofeh Medical Center
Be'er Ya'akov, Israel, 70300
Rambam Health Care Campus
Haifa, Israel, 3109601
Shaare Zedek Medical Center
Jerusalem, Israel, 91031
Hadassah University Hospital
Jerusalem, Israel, 91120
Sheba Medical Center
Ramat Gan, Israel, 5262100
Kaplan Medical Center
Rehovot, Israel, 76100
Italy
Ospedale Classificato Equiparato Sacro Cuore-Don Calabria
Negrar, Verona, Italy, 37024
Centro di Riferimento Oncologi
Aviano, Italy, 33081
Ospedale San Raffaele IRCCS
Milan, Italy, 20132
Istituto Europeo di Oncologia
Milan, Italy, 20141
AO Bianchi Melacrino Morelli
Reggio Calabria, Italy, 89125
Korea, Republic of
National Cancer Center
Goyang, Gyeonggido, Korea, Republic of, 10408
Samsung Medical Center
Gangnam-gu, Seoul Teugbyeolsi, Korea, Republic of, 06351
Seoul National University Hospital
Jongno-gu, Seoul Teugbyeolsi, Korea, Republic of, 03080
Severance Hospital
Seoul, Seoul Teugbyeolsi, Korea, Republic of, 03722
Asan Medical Center
Seoul, Seoul Teugbyeolsi, Korea, Republic of, 05505
Korea University Anam Hospital
Seoul, Korea, Republic of, 02841
Latvia
Riga East Clinical Univ Hosp
Riga, Latvia, 1038
P. Stradins Clinical Univ Hosp
Riga, Latvia, LV-1002
Lithuania
Hosp Lithuanian Univ Health Sc
Kovno, Kaunas, Lithuania, 50009
National Cancer Institute
Vilnius, Lithuania, 08660
Mexico
Centro Oncologico de Chihuahua
Chihuahua, Mexico, 31217
Centro Multidisciplinario para
Mérida, Mexico, 97133
Instituto Nacional del Cancer
Tlapan, Mexico, 14080
Netherlands
Univ Med Center Groningen
Groningen, Netherlands, 9713 GZ
Maastricht University Med Ctr
Maastricht, Netherlands, 6229 HX
Erasmus Medisch Centrum
Rotterdam, Netherlands, 3015 CE
Norway
Haukeland University Hospital
Bergen, Norway, 5021
Poland
Centrum Onkologii Lukaszczyka
Bydgoszcz, Poland, 85-796
Wojewodzki Szpital Zespolony
Elblag, Poland, 82-300
Wojewodzkie Wielospecjalistycz
Lodz, Poland, 93-509
Mrukmed. Lekarz Beata Madej
Rzeszow, Poland, 35-922
Wojewodzki Szpital Specjalisty
Wroclaw, Poland, 51-124
Portugal
Centro Hospitalar De Vila Nova
Vila Nova De Gaia, Porto, Portugal, 4434-502
Centro Hospitalar do Algarve
Faro, Portugal, 8000-386
Centro Hospitalar Lisboa Norte, EPE
Lisboa, Portugal, 1649-035
Unidade Local Saude Matosinhos
Matosinhos, Portugal, 4464-513
IPO Porto FG, EPE
Porto, Portugal, 4200-072
Centro Hospitalar de Sao Joao, EPE
Porto, Portugal, 4200-319
Puerto Rico
Ad-Vance Medical Research, LLC
Ponce, Puerto Rico, 00717
Romania
S.C. Centrul de Oncologie Sf. Nectarie S.R.L.
Craiova, Dolj, Romania, 200347
lnstitutul Oncologic Trestiore
Bucharest, Romania, 022328
Spitalul Clinic Judetean de Ur
Cluj, Romania, 400006
Oncomed SRL
Timisoara, Romania, 300239
Russian Federation
Sverdlovsk Regional Oncology Center
Ekaterinburg, Sverdlovskaya Oblast, Russian Federation, 620043
Kursk Regional Oncology Dispen
Kursk, Tatarstan, Respublika, Russian Federation, 305035
archangel Clinical Oncology
Arkhangelsk, Russian Federation, 163045
Altay Regional Oncologic Disp
Barnaul, Russian Federation, 656049
Belgorod Oncology Dispensary
Belgorod, Russian Federation, 308010
GBOU VPO Saratov State Med Uni
Saratov, Russian Federation, 410012
LLC BioEq Ltd.
St. Petersburg, Russian Federation, 197342
Siberian State Med Uni
Tomsk, Russian Federation, 634050
Volgograd Reg Onc Disp #3
Volzhsky, Russian Federation, 404130
Singapore
National University Hospital
Singapore, Singapore, 119074
Gleneagles Medical Centre
Singapore, Singapore, 258499
Johns Hopkins Singapore IMC
Singapore, Singapore, 308433
South Africa
GVI Oncology
Port Elizabeth, Eastern Cape, South Africa, 6006
Universitas Annexe
Bloemfontein, Free State, South Africa, 9320
Medical Oncology Ctr Rosebank
Johannesburg, Gauteng, South Africa, 2196
Sandton Oncology Centre
Johannesburg, Gauteng, South Africa, 2199
Mary Potter Oncology Centre
Pretoria, Gauteng, South Africa, 0181
The Oncology Centre
Durban, Kwazulu-Natal, South Africa, 4091
Netcare Oncology Intervent Ctr
Cape Town, Western Cape, South Africa, 7460
Cancercare Outeniqua Oncology Unit
George, Western Cape, South Africa, 6530
Spain
Hosp Santa Creu i Sant Pau
Barcelona, Spain, 08026
Hospital General Universitario Gregorio Maranon
Madrid, Spain, 28009
Hosp Univ Madrid Sanchinarro
Madrid, Spain, 28050
Hosp Uni Virgen de la Victoria
Malaga, Spain, 29010
Hosp Clin Univ de Valencia
Valencia, Spain, 46010
Sweden
Skanes Universitetssjukhus
Malmö, Skane Lan, Sweden, 214 28
Sahlgrenska University Hosp
Goteborg, Sweden, 413 45
Karolinska Univ Sjukhuset
Solna, Sweden, 17176
Norrlands Universitetssjukhus
Umeå, Sweden, 90185
Uppsala University Hospital
Uppsala, Sweden, 75185
Taiwan
National Taiwan Univ Hosp
Taipei City, Taipei, Taiwan, 10002
Kaohsiung Medical University
Kaohsiung, Taiwan, 80708
Turkey
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi
Tunceli, Ankara, Turkey, 62000
Hacettepe University Medical Faculty
Ankara, Turkey, 06100
Akdeniz University Medical Fac
Antalya, Turkey, 07059
Bezmi alem Vakif Universitesi
Istanbul, Turkey, 34093
Istanbul University Istanbul Medical Faculty
Istanbul, Turkey, 34093
Ukraine
Cherkassy Regional Onc Ctr
Cherkasy, Ukraine, 18000
City Multi-Field Clin Hosp #4
Dnipropetrovsk, Ukraine, 49102
Kharkiv Regional Clinical Onco
Kharkiv, Ukraine, 61070
Kryorizskiy Oncology Dispensa
Kryvyi Rih, Ukraine, 50048
Lviv State Onc Local Treatment
Lviv, Ukraine, 79031
Poltava Regional Clinical Onco
Poltava, Ukraine, 36011
Zaporizhzhia Med. Academy MOH
Zaporizhia, Ukraine, 69040
United Kingdom
University of Birmingham
Birmingham, United Kingdom, B15 2TT
Bristol Haematology and Onc Ct
Bristol, United Kingdom, BS2 8ED
Castle Hill Hospital
Cottingham, United Kingdom, HU16 5JQ
Nottingham Univ Hospitals NHS
Nottingham, United Kingdom, NG5 1PB
Sponsors and Collaborators
AbbVie
Investigators
Study Director: AbbVie Inc. AbbVie

Additional Information:
Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT02163694     History of Changes
Other Study ID Numbers: M12-914
2014-000345-70 ( EudraCT Number )
First Posted: June 16, 2014    Key Record Dates
Last Update Posted: May 16, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by AbbVie:
PARP Inhibitor
Veliparib
BRCA1
BRCA2
HER2-negative
Locally recurrent
Breast Cancer
Metastatic Breast Cancer
ABT-888
Genetic breast cancer
Paclitaxel
BRCA Mutation
PARP
Carboplatin

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Veliparib
Albumin-Bound Paclitaxel
Carboplatin
Poly(ADP-ribose) Polymerase Inhibitors
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors